# An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN

Source: https://onco.cc/trials/nct03897881/  
OnCo record `nct03897881` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Intismeran autogene, Pembrolizumab in melanoma, run by ModernaTX, Inc., active and no longer recruiting.

## Summary

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) is a phase 2 interventional study registered as NCT03897881 by ModernaTX, Inc., with 267 participants enrolled, started 2019-07-18 and due to reach its primary completion in 2032-11-21. Interventions recorded: mRNA-4157, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03897881
- Phase: 2
- Setting: A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)
- Sponsor: ModernaTX, Inc.
- Enrolled: 267

## Sources

- ClinicalTrials.gov NCT03897881: https://clinicaltrials.gov/study/NCT03897881

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Stage III melanoma (after surgery)](https://onco.cc/cancers/stage-iii-melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Moderna](https://onco.cc/companies/moderna/)
- key papers: [Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study](https://onco.cc/key-papers/paper-nct03897881-j-clin-oncol-2026-update/), [KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery](https://onco.cc/key-papers/paper-keynote-942-lancet-2024/)

---
JSON: https://onco.cc/api/v1/entities/nct03897881.json